Finasteride is effective for the treatment of central serous chorioretinopathy

Abstract

Purpose To evaluate the safety and efficacy of finasteride treatment in patients with central serous chorioretinopathy (CSC). Methods Retrospective review of 29 eyes of 23 patients who were treated with finasteride for CSC. Previous medical and ocular history, steroid use, length of finasteride treatment, additional treatments for CSC, visual acuity (VA), central macular thickness (CMT), and presence of subretinal fluid (SRF) throughout the follow-up period, and the occurrence of any complications were recorded. Results Initial VA was 0.29 ± 0.31 logMAR, and a trend towards improved VA was noted after 3 months (0.25 ± 0.36 logMAR; P = 0.07). VA was significantly improved at the final follow-up (0.23 ± 0.27 logMAR; P = 0.024). Initial CMT was 354 ± 160 μm, and was significantly reduced after 1 month of treatment (284 ± 77 μm; P = 0.002) and this was maintained to the end of follow-up (247 ± 85 μm; P = 0.001). A significant reduction in SRF presence was found at all time points, with an overall 75.9% rate of complete resolution. Following discontinuation, SRF recurrence was noted in 37.5% of cases. No adverse events were recorded. Conclusions Finasteride is a safe and effective treatment for CSC. It may be a possible new option for the initial management of patient with CSC, and a suggested treatment approach is presented.

Diagnosed a Patient with Central Serous Chorioretinopathy? Now What?: Management of Central Serous Chorioretinopathy

“…As a whole, these have had poor evidence, including: rifampin, 18 Helicobacter Pylori treatment, 19–21 carbonic anhydrase inhibitors 22,23 , finasteride 24 , beta-blockers, 25 antioxidants, 26–28 aspirin. 29 Mineralocorticoid receptor antagonists appear to be the most promising of the systemic medications used in the management of CSCR.…”

The efficacy and use of finasteride in women: a systematic review

“…Central serous chorioretinopathy (CSCR) is an acquired idiopathic chorioretinal disorder characterized by exudative detachment of the retina and/or retinal pigment epithelium (RPE) . The first study of finasteride use for treatment of CSCR in women reported no significant change in visual acuity, a modest reduction in macular thickness, and improvement in subretinal fluid levels …”

“…76 Central serous chorioretinopathy Central serous chorioretinopathy (CSCR) is an acquired idiopathic chorioretinal disorder characterized by exudative detachment of the retina and/or retinal pigment epithelium (RPE). 77 The first study of finasteride use for treatment of CSCR in women reported no significant change in visual acuity, a modest reduction in macular thickness, and improvement in subretinal fluid levels. 77 Fertility A pilot study examining finasteride (5 mg/day) therapy on normal ovulatory women (n = 5) demonstrated no alteration in follicular development or in ovulation.…”

“…77 The first study of finasteride use for treatment of CSCR in women reported no significant change in visual acuity, a modest reduction in macular thickness, and improvement in subretinal fluid levels. 77 Fertility A pilot study examining finasteride (5 mg/day) therapy on normal ovulatory women (n = 5) demonstrated no alteration in follicular development or in ovulation. 78 However, a 33-year-old hyperandrogenic woman who failed to ovulate after rFSH (150 IU) stimulation had finasteride (5 mg/day) added to her treatment for 16 days and delivered a normal male infant 40 weeks later.…”

Atualização em Coriorretinopatia Serosa Central

“…Houve resolução total em 75.9% e recorrência após descontinuação em 37,5% dos casos. (14) Rifampicina oral: o efeito do tratamento oral com rifampicina (300 mg 2 vezes ao dia por 3 meses) na CSC crônica com duração média de 28,4 meses foi investigado por um estudo prospectivo com 14 olhos. Resultou na melhora da acuidade visual, redução da espessura da retina e coroide e resolução total do fluido sub-retiniano em 42,8% e parcial em 64% dos olhos.…”